Drug intelligence / Profile preview

tobramycin + gentamicin sulfate + amikacin sulfate

Development stage: Unknown
Lead developer: Insmed
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Inhalation, Intrathecal, Topical, Ophthalmic

Overview

This is a combination of three aminoglycoside antibiotics (tobramycin, gentamicin sulfate, and amikacin sulfate) that work by inhibiting bacterial protein synthesis. Aminoglycosides bind to the 30S ribosomal subunit, interfering with protein synthesis and resulting in bacterial death. This combination is used to treat serious bacterial infections, particularly those caused by aerobic gram-negative bacilli. The three components may be used together for empiric treatment of severe infections where broad coverage against resistant gram-negative organisms is needed.

Targets

Bacterial Ribosome

Beyond the preview

Go deeper on tobramycin + gentamicin sulfate + amikacin sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tobramycin + gentamicin sulfate + amikacin sulfate.

Explore the full profile